Stevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including hearing disorders and schizophrenia,…
Read More
Stevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for schizophrenia, hearing loss and other serious brain disorders, today…
Read More
Stevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the…
Read More
• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of the potential for AUT00206 to treat psychiatric disorders such as…
Read More
